Healthcare Finance News February 8, 2019
There’s a whole lot of finger pointing among feds, providers, payers, PBMs, big pharma, in what Azar calls “dirty, little secret of drug pricing.”
Providers, payers, pharmacists, pharmacy benefit managers, drug manufacturers and consumers all have a stake in the recent proposal by the Department of Health and Human Services to lower the cost of prescription drugs by taking away kickback protections on rebates.
Reaction to the proposal has varied. America’s Health Insurance Plans and pharmacy benefit managers say it’s the drug manufacturers that set the prices, and it’s hard not to point the blame at pharmaceutical companies when prices for orphan drugs to treat rare diseases have sometimes increased by thousands of dollars, for no obviously perceivable reason.
But...
Today's Sponsors
Today's Sponsor